Drug reference
HIV infection resistant to other protease inhibitors, in combination with other antiretroviral drugs in patients previously treated with antiretrovirals–with low-dose ritonavir Infection ▶BY MOUTH USING CAPSULES ▶Adult: 500 mg twice daily DOSE EQUIVALENCE AND CONVERSION ▶The bioavailability of tipranavir oral solution is higher than that of the capsules; the oral solution is not interchangeable with the capsules on a milligram-for- milligram basis.
PDF page 719
Abnormal liver function tests and/or signs or symptoms of liver injury (consider delaying treatment if serum transaminases are greater than 5 times the upper limit of normal—consult product literature). patients at risk of increased bleeding from trauma, surgery or other pathological conditions
PDF page 719
Flavours of oral liquid formulations may include toffee and mint.
PDF page 719
→Appendix 1: HIV-protease inhibitors
PDF page 719
▶Uncommon Hyperamylasaemia. hyperglycaemia. influenza like illness. renal failure. thrombocytopenia ▶Rare or very rare Dehydration. hyperbilirubinaemia. intracranial haemorrhage ▶Frequency not known Bleeding tendency SIDE-EFFECTS, FURTHER INFORMATION Potentially life- threatening hepatotoxicity reported. Discontinue if signs or symptoms of hepatitis develop or if liver-function abnormality develops (consult product literature).
PDF page 719
Manufacturer advises use only if potential benefit outweighs risk—toxicity in animal studies.
PDF page 719
Manufacturer advises caution in mild impairment (risk of increased exposure)—monitor liver function before treatment, then every two weeks for 3 months, then monthly until 48 weeks, then every 8 to 12 weeks thereafter, and discontinue if liver function worsens; avoid in moderate to severe impairment.
PDF page 719
Monitor liver function before treatment, then every 2 weeks for 1 month, then every 4 weeks until 24 weeks, then every 8 to 12 weeks thereafter.
PDF page 719
There can be variation in the licensing of different medicines containing the same drug. Capsule CAUTIONARY AND ADVISORY LABELS 5, 21 EXCIPIENTS: May contain Ethanol ▶Aptivus (Boehringer Ingelheim Ltd) Tipranavir 250 mg Aptivus 250mg capsules | 120 capsule P £441.00 ANTIVIRALS › OTHER
PDF pages 719, 720
Patients or carers should be told to observe the oral solution for crystallisation; the bottle should be replaced if more than a thin layer of crystals form (doses should continue to be taken at the normal time until the bottle is replaced).
PDF page 719
500 mg twice daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 719
